THBD and acute promyelocytic leukemia: Notably, targeting reduced levels of thrombomodulin with recombinant human thrombomodulin (rTM) to stabilize the coagulopathy of APL has been reported in Japan; early-phase clinical trials have shown it corrects aspects of coagulopathy in some patients with APL [99,100,101,102].